Gene expression profiling by RNA-seq of newly diagnosed multiple myeloma patients included in the HOVON95 clinical trial

This gene expression set contains data from patients included in the HOVON95 clinical trial. Using this data the technical comparison between microarray and RNAseq was made. Circulating tumor cells are a known prognostic factor in multiple myeloma. However, the causes of high circulating tumor cells have been insufficiently characterised. This study aimed to identify factors involved in high circulating tumor cell count, using a model to correct for important contributing factors to this phenotype, which is closely associated with aggressive disease. To validate that the gene expression patterns identified in microarray data were similar in RNAseq data, the current set of RNAseq data was used. In addition, this RNAseq dataset is part of the Horizon2020 MMpredict study, and was in part funded using European funding from MMpredict. Raw data not provided due to patient privacy concerns.

本基因表达数据集包含来自HOVON95临床试验入组患者的样本数据。本数据集被用于开展微阵列（microarray）与RNA测序（RNAseq）的技术对比研究。循环肿瘤细胞（circulating tumor cells, CTCs）是多发性骨髓瘤（multiple myeloma）中已被证实的预后因子，然而高循环肿瘤细胞负荷的成因尚未得到充分阐明。本研究旨在明确与高循环肿瘤细胞计数相关的影响因素，通过构建模型校正该表型的重要混杂因素——该表型与侵袭性疾病密切相关。为验证微阵列数据中鉴定出的基因表达模式在RNAseq数据中同样存在，本研究使用了当前的这套RNAseq数据集。此外，本RNAseq数据集属于Horizon2020框架下MMpredict研究的一部分，且部分经费由MMpredict的欧洲项目资助。鉴于患者隐私保护相关要求，本数据集未提供原始数据。